“Everyone was very pleasant. I felt at ease and not nervous. Would recommend to family and friends.”
Ischemic vs. Non-Ischemic CRVO: Why the Difference Matters for Your Care
How We Tell the Two Types Apart
Classifying a CRVO requires combining several sources of information gathered during a dilated exam and specialized imaging. No single finding settles the question on its own.
During a dilated eye exam, your Retina Specialist assesses how much blood is spread across the retina, how many cotton-wool spots are visible, and how the optic nerve head appears. The pupil test, performed by swinging a light between both eyes, is particularly informative. A relative afferent pupillary defect, meaning one pupil reacts less strongly to direct light than the other, points strongly toward the ischemic form. Vision worse than 20/200 does the same. An electroretinogram, which measures the electrical response of the retina to light, may be used in certain cases and can show a reduced signal consistent with ischemic damage. None of these tests are painful or require any injections.
Two imaging tools carry the most weight in classifying CRVO. Optical coherence tomography, or OCT, is a painless light-based scan that measures exactly how much the macula has swollen. Fluorescein angiography uses a dye injected into a vein in your arm to photograph which capillaries still fill with blood and which have shut down. A dye-free version called OCT angiography can also map blood flow in the retinal layers. The ischemic threshold is drawn at 10 or more disc areas that do not fill on the angiogram. Our team also uses wide-field imaging and B-scan ultrasound when needed to get the clearest possible picture of the retina.
Heavy retinal bleeding can block the view and make it impossible to grade perfusion accurately at a first visit. In those situations, the eye may be classified as indeterminate rather than forced into one category. As the blood clears over the following weeks, the imaging picture becomes clearer and a classification can be made. Hearing 'we will know more in a few weeks' is a normal and honest answer at the earliest visits, not a reason for concern.
The classification is a snapshot, not a permanent assignment. Research shows that roughly 34 out of every 100 eyes that started as non-ischemic had converted to ischemic within three years, with about 15 out of every 100 converting within the first four months. Conversion usually announces itself as a noticeable further drop in vision. This possibility is a core reason why follow-up appointments matter even when you feel your vision is stable.
How the Two Types Compare Side by Side
The features your Retina Specialist weighs are interconnected and are read as a whole picture. The comparisons below summarize the key differences between the two forms.
At the time of diagnosis, the two types tend to look quite different on exam and on imaging.
- Share of cases: roughly 70 out of every 100 are non-ischemic; about 30 out of every 100 are ischemic.
- Typical starting vision: often better than 20/200 in non-ischemic eyes; worse than 20/200 in over 90 out of every 100 ischemic eyes.
- Pupil reaction: mild or absent defect in non-ischemic eyes; a relative afferent pupillary defect is typical in ischemic eyes.
- Retinal appearance: milder bleeding in non-ischemic eyes; heavy deep bleeding and many cotton-wool spots in ischemic eyes.
- Angiography finding: capillaries still fill in non-ischemic eyes; at least 10 disc areas do not fill in ischemic eyes.
These features serve as a guide. The full picture, not any single finding, determines the classification.
The risk profile for complications differs substantially between the two forms over months and years.
- New blood vessels on the iris or in the drainage angle: appear in about 10 out of every 100 non-ischemic eyes and in about 35 out of every 100 ischemic eyes.
- Neovascular glaucoma (a serious pressure complication driven by abnormal new vessels): rare after non-ischemic CRVO; present in at least 23 out of every 100 ischemic eyes within 15 months in untreated data.
- Category change over three years: up to 34 out of every 100 non-ischemic eyes converted to ischemic; ischemic eyes do not revert to non-ischemic.
These are group averages from studies of many eyes. They describe how often something happened in a population and cannot predict what will happen in your specific eye.
Treatment: What Changes and What Stays the Same
Both types of CRVO often require treatment, but the goals and monitoring schedules differ. The type and timing of each intervention depend on which form you have and how your eye is responding over time.
Macular edema, the swelling of the macula that blurs central vision, is treated the same way in both types because the swelling responds to the same medications. Intravitreal anti-VEGF injection is the first-line treatment for macular edema caused by a retinal vein occlusion. Anti-VEGF drugs, which include agents such as Avastin, Lucentis, Eylea, and Vabysmo, work by blocking the chemical signal that drives fluid leakage and abnormal vessel growth. In a large randomized trial, monthly bevacizumab and monthly aflibercept each produced an average gain of about 19 letters of vision at six months, and the two were found to be equivalent in effectiveness. A steroid implant placed inside the eye, such as Iluvien, is another option in certain situations and is something your Retina Specialist can discuss with you.
Panretinal photocoagulation, or PRP, is a scatter laser treatment applied to the oxygen-starved outer retina to quiet the chemical signals that drive abnormal new vessel growth. Research from the Central Vein Occlusion Study found that applying laser before new vessels appeared did not significantly reduce the rate of new vessel development. By contrast, prompt laser applied at the first sign of new vessels led to clearing in a higher proportion of eyes than in those that had received early preventive laser. The general approach supported by that evidence is close monitoring with prompt laser the moment new vessels are detected. Our team weighs that evidence alongside the role of anti-VEGF therapy when planning your care, and your individual plan may reflect both.
Visit frequency is where the two types diverge most sharply. Non-ischemic eyes are commonly rechecked at around three months after diagnosis, while ischemic eyes are typically seen monthly for the first six months, with monitoring continuing for up to about two years. Those early visits in ischemic cases include a look at the iris and the drainage angle of the eye, which is where new blood vessels first appear before causing pressure problems. Catching them at that stage gives treatment the best chance of working. Injection visits and monitoring visits may be scheduled separately, and our team will walk you through your specific schedule at each appointment.
A retinal vein occlusion is partly a blood vessel event, so evaluation reaches beyond the eye itself. Blood pressure, blood sugar, cholesterol, and blood counts are checked in everyone with this diagnosis. A broader clotting and inflammatory workup is added for people under 50, for cases affecting both eyes, or for those with a personal history of clotting disorders. The known risk factors for CRVO include high blood pressure, diabetes, open-angle glaucoma, and high cholesterol, and the great majority of patients are over 50. Managing these conditions is care for your entire circulation, not only your eye.
Complications, Risks, and a Realistic Outlook
Understanding what to realistically expect helps you make informed decisions and stay engaged in your follow-up care. The outlook varies considerably between the two types and between individuals within each type.
Starting vision is the most useful single predictor of long-term visual outcome. In the Central Vein Occlusion Study, about 65 out of every 100 eyes that began at 20/40 or better maintained that level through follow-up, while about 80 out of every 100 eyes that began worse than 20/200 stayed in that range. Eyes in the middle range were more variable, with some improving, some holding, and some declining. Those figures describe the untreated natural course from an era before anti-VEGF injections, so they do not reflect what current treatment adds. With monthly anti-VEGF injections, large randomized trials have shown average vision gains that were not seen in untreated historical data. These are group averages and are not a forecast for any individual eye.
Retinal tissue that is short of oxygen releases chemical distress signals, chiefly a protein called VEGF. Those signals push the eye to grow fragile new blood vessels, but those vessels tend to grow in the wrong places: on the iris and in the drainage angle at the front of the eye. When new vessels obstruct the drainage angle, eye pressure rises sharply. This is neovascular glaucoma, and it is the complication that makes monthly monitoring in ischemic eyes so important. Research shows that new vessels on the iris or in the angle appeared in about 35 out of every 100 ischemic eyes, compared to about 10 out of every 100 non-ischemic eyes. Caught at the stage of new vessel growth, the condition responds to laser and anti-VEGF treatment more reliably than it does once it has fully taken hold.
For a non-ischemic occlusion, the realistic goal is stable or improved central vision once the macular swelling is treated. There is also a real chance of conversion to the ischemic form, and follow-up is specifically designed to detect that early. For an ischemic occlusion, central vision is often significantly affected from the start, and the primary goal shifts toward protecting the eye from pressure damage and keeping it comfortable and functional. Neither type comes with guarantees, and neither outlook is a prediction about what will happen in your eye specifically.
When to Call Us After a Vein Occlusion
Knowing which changes require a same-day call and which can wait until your next visit helps you respond appropriately without unnecessary worry.
Some symptoms should not wait for your next scheduled appointment. Contact us the same day if you notice any of the following.
- Severe eye pain or a red, painful eye.
- Rainbow halos around lights combined with new blurring of vision.
- A rapid drop in vision over the course of a day.
- A sudden shower of new floaters or flashing lights.
- A dark curtain or shadow appearing in any part of your vision.
- Eye pain accompanied by a headache or nausea.
When you call, let us know that you have had a central retinal vein occlusion, describe the change, and tell us when it started. That information helps us get you seen at the right level of urgency. Most calls like this end in reassurance, and the ones that do not are exactly the ones worth making.
Other changes are less urgent but still worth reporting before your next visit. These include blur creeping back after a period of stability, new distortion in straight lines, a fresh dark spot in the center of your vision, or a gradual increase in floaters rather than a sudden appearance. These changes often signal that macular swelling has returned and that treatment may be due sooner than your next scheduled appointment. Report any sudden changes in the other eye as well, since it shares the same blood pressure, blood sugar, and eye pressure risks that contributed to the first event.
Central retinal vein occlusion is managed by a Retina Specialist because the imaging, injections, and laser treatments all fall within that specialty. Your optometrist or primary care provider often stays involved for glasses, pressure checks, and the whole-body risk factors that contributed to the occlusion. If eye pressure is elevated or new vessel glaucoma develops, a glaucoma specialist may also become part of your care team. Ask at each visit who is tracking your appointment interval, particularly if you have an ischemic occlusion. An appointment that quietly drifts from monthly to every few months is the gap this monitoring schedule is specifically designed to close.
Frequently Asked Questions
These answers address specific questions about diagnosis, decisions, and daily life with a CRVO that may not be fully covered elsewhere on this page.
Ask your Retina Specialist directly. The classification is already in your chart, but it is worth reviewing together so you understand what was used to reach it. If the imaging at your first visit was limited by heavy bleeding, you may have been classified as indeterminate. That is a temporary designation, not a permanent one. As the blood absorbs over the following weeks, the angiogram can be repeated and a more definitive classification can be made.
Yes, in terms of both starting vision and long-term risk. Ischemic eyes present with significantly worse vision and carry a substantially higher risk of new vessel growth and the glaucoma it can cause. More serious in this context means closer monitoring, different treatment targets, and a greater need for prompt reporting of new symptoms. It does not mean nothing can be done. Treatment can protect the eye from pressure damage even when central vision has been significantly affected.
It can, and that possibility is one of the main reasons follow-up continues even when you feel your vision has stabilized. Research shows that a meaningful proportion of initially non-ischemic eyes converted to ischemic within the first three years, with some converting within the first four months. Conversion usually shows up as a noticeable worsening of vision. Do not wait for your next scheduled appointment if your vision drops. That change is worth a same-day call.
The honest answer depends heavily on which type you have, where your vision started, and how well the macular swelling responds to treatment. Historical data from untreated eyes showed that most eyes starting with good vision maintained it, while most eyes starting with very poor vision stayed poor. Modern anti-VEGF treatment has changed the outlook meaningfully by reducing swelling and protecting the macula over time. Your Retina Specialist can walk you through your OCT measurements visit to visit, which gives a more concrete picture of how your macula is responding than vision charts alone.
Macular swelling can be present and actively damaging the central retina even when your vision still reads reasonably well on a chart, particularly in the early weeks. Treating the swelling while vision is good is aimed at protecting what you have. Waiting for vision to decline before acting means starting from a lower baseline. If you are uncertain why injections were recommended, ask to see your OCT scan. The thickness measurement is easy to track visit to visit and often makes the recommendation much easier to understand.
The most effective steps involve managing the shared risk factors with your primary care provider: blood pressure, blood sugar, and cholesterol control, along with not smoking. Eye pressure should also be monitored, since open-angle glaucoma is among the recognized risk factors. If you are under 50, or if you have had clotting events in the past, a broader workup for clotting disorders may be recommended. These steps are not a guarantee against a future event, but they represent the strongest levers available for reducing that risk.
Schedule a Visit With Our Team
At Atlantic Retina Center, our fellowship-trained Retina Specialists focus exclusively on the retina, vitreous, and macula, and we bring that depth of specialization to every aspect of CRVO care, from initial classification through long-term monitoring and treatment. If you have been diagnosed with a central retinal vein occlusion or are concerned about your vision, we welcome you to schedule an evaluation at one of our offices across the Delmarva peninsula. Early, expert care makes a meaningful difference in what is possible for your vision and the long-term health of your eye.